Cardiff Oncology, Inc. (CRDF): Operating Income
-$48.96M
Year ended 2025-12-31
-$42.27M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$48.96M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$48.65M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$45.41M | n/m | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | -$39.90M | n/m | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | -$28.86M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$19.09M | n/m | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | -$16.68M | n/m | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | -$17.05M | n/m | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | -$25.60M | n/m | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | -$40.15M | n/m | 2018-02-26, From 2016-01-01 |
| 2015-12-31 | -$25.27M | n/m | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | -$14.95M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | -$10.69M | n/m | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | -$4.85M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$2.98M | n/a | 2014-03-17, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.96M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.45M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$165.01M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$24.94M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$135.03M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$7.54M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$67.06M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$77.63M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$108.14M | n/m |
Compare CRDF, IMA, PROK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗